Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Gene Therapy Market

ID: MRFR/Pharma/51497-HCR
200 Pages
Nidhi Mandole
Last Updated: February 06, 2026

UK Gene Therapy Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders), By Technology (Viral Vectors, CRISPR, Gene Editing, RNA Therapy, Non-Viral Methods), By Applications (Research, Clinical, Commercial) and By Route of Administration (Intravenous, Intramuscular, Intradermal, Intrathecal, Oral) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Gene Therapy Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Life Sciences, BY Vector Type (USD Million)
  49.     4.1.1 Viral Vector
  50.     4.1.2 Non-Viral Vector
  51.   4.2 Life Sciences, BY Gene Type (USD Million)
  52.     4.2.1 Antigen
  53.     4.2.2 Cytokine
  54.     4.2.3 Tumor Suppressor
  55.     4.2.4 Suicide
  56.     4.2.5 Deficiency
  57.     4.2.6 Growth Factors
  58.     4.2.7 Receptors
  59.     4.2.8 Others
  60.   4.3 Life Sciences, BY Application (USD Million)
  61.     4.3.1 Oncological Disorders
  62.     4.3.2 Rare Diseases
  63.     4.3.3 Cardiovascular Diseases
  64.     4.3.4 Neurological Disorders
  65.     4.3.5 Infectious Diseases
  66.     4.3.6 Others
  67.   4.4 Life Sciences, BY Delivery Method (USD Million)
  68.     4.4.1 In Vivo Gene Therapy
  69.     4.4.2 Ex Vivo Gene Therapy
  70. 5 SECTION V: COMPETITIVE ANALYSIS
  71.   5.1 Competitive Landscape
  72.     5.1.1 Overview
  73.     5.1.2 Competitive Analysis
  74.     5.1.3 Market share Analysis
  75.     5.1.4 Major Growth Strategy in the Life Sciences
  76.     5.1.5 Competitive Benchmarking
  77.     5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  78.     5.1.7 Key developments and growth strategies
  79.       5.1.7.1 New Product Launch/Service Deployment
  80.       5.1.7.2 Merger & Acquisitions
  81.       5.1.7.3 Joint Ventures
  82.     5.1.8 Major Players Financial Matrix
  83.       5.1.8.1 Sales and Operating Income
  84.       5.1.8.2 Major Players R&D Expenditure. 2023
  85.   5.2 Company Profiles
  86.     5.2.1 Novartis (CH)
  87.       5.2.1.1 Financial Overview
  88.       5.2.1.2 Products Offered
  89.       5.2.1.3 Key Developments
  90.       5.2.1.4 SWOT Analysis
  91.       5.2.1.5 Key Strategies
  92.     5.2.2 Gilead Sciences (US)
  93.       5.2.2.1 Financial Overview
  94.       5.2.2.2 Products Offered
  95.       5.2.2.3 Key Developments
  96.       5.2.2.4 SWOT Analysis
  97.       5.2.2.5 Key Strategies
  98.     5.2.3 Sangamo Therapeutics (US)
  99.       5.2.3.1 Financial Overview
  100.       5.2.3.2 Products Offered
  101.       5.2.3.3 Key Developments
  102.       5.2.3.4 SWOT Analysis
  103.       5.2.3.5 Key Strategies
  104.     5.2.4 Bluebird Bio (US)
  105.       5.2.4.1 Financial Overview
  106.       5.2.4.2 Products Offered
  107.       5.2.4.3 Key Developments
  108.       5.2.4.4 SWOT Analysis
  109.       5.2.4.5 Key Strategies
  110.     5.2.5 Spark Therapeutics (US)
  111.       5.2.5.1 Financial Overview
  112.       5.2.5.2 Products Offered
  113.       5.2.5.3 Key Developments
  114.       5.2.5.4 SWOT Analysis
  115.       5.2.5.5 Key Strategies
  116.     5.2.6 CRISPR Therapeutics (CH)
  117.       5.2.6.1 Financial Overview
  118.       5.2.6.2 Products Offered
  119.       5.2.6.3 Key Developments
  120.       5.2.6.4 SWOT Analysis
  121.       5.2.6.5 Key Strategies
  122.     5.2.7 Bristol-Myers Squibb (US)
  123.       5.2.7.1 Financial Overview
  124.       5.2.7.2 Products Offered
  125.       5.2.7.3 Key Developments
  126.       5.2.7.4 SWOT Analysis
  127.       5.2.7.5 Key Strategies
  128.     5.2.8 Roche (CH)
  129.       5.2.8.1 Financial Overview
  130.       5.2.8.2 Products Offered
  131.       5.2.8.3 Key Developments
  132.       5.2.8.4 SWOT Analysis
  133.       5.2.8.5 Key Strategies
  134.     5.2.9 AstraZeneca (GB)
  135.       5.2.9.1 Financial Overview
  136.       5.2.9.2 Products Offered
  137.       5.2.9.3 Key Developments
  138.       5.2.9.4 SWOT Analysis
  139.       5.2.9.5 Key Strategies
  140.   5.3 Appendix
  141.     5.3.1 References
  142.     5.3.2 Related Reports
  143. 6 LIST OF FIGURES
  144.   6.1 MARKET SYNOPSIS
  145.   6.2 UK MARKET ANALYSIS BY VECTOR TYPE
  146.   6.3 UK MARKET ANALYSIS BY GENE TYPE
  147.   6.4 UK MARKET ANALYSIS BY APPLICATION
  148.   6.5 UK MARKET ANALYSIS BY DELIVERY METHOD
  149.   6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
  150.   6.7 RESEARCH PROCESS OF MRFR
  151.   6.8 DRO ANALYSIS OF LIFE SCIENCES
  152.   6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
  153.   6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
  154.   6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
  155.   6.12 LIFE SCIENCES, BY VECTOR TYPE, 2024 (% SHARE)
  156.   6.13 LIFE SCIENCES, BY VECTOR TYPE, 2024 TO 2035 (USD Million)
  157.   6.14 LIFE SCIENCES, BY GENE TYPE, 2024 (% SHARE)
  158.   6.15 LIFE SCIENCES, BY GENE TYPE, 2024 TO 2035 (USD Million)
  159.   6.16 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
  160.   6.17 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
  161.   6.18 LIFE SCIENCES, BY DELIVERY METHOD, 2024 (% SHARE)
  162.   6.19 LIFE SCIENCES, BY DELIVERY METHOD, 2024 TO 2035 (USD Million)
  163.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  164. 7 LIST OF TABLES
  165.   7.1 LIST OF ASSUMPTIONS
  166.     7.1.1
  167.   7.2 UK MARKET SIZE ESTIMATES; FORECAST
  168.     7.2.1 BY VECTOR TYPE, 2025-2035 (USD Million)
  169.     7.2.2 BY GENE TYPE, 2025-2035 (USD Million)
  170.     7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  171.     7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Million)
  172.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  173.     7.3.1
  174.   7.4 ACQUISITION/PARTNERSHIP
  175.     7.4.1

UK Life Sciences Market Segmentation

Life Sciences By Vector Type (USD Million, 2025-2035)

  • Viral Vector
  • Non-Viral Vector

Life Sciences By Gene Type (USD Million, 2025-2035)

  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide
  • Deficiency
  • Growth Factors
  • Receptors
  • Others

Life Sciences By Application (USD Million, 2025-2035)

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Others

Life Sciences By Delivery Method (USD Million, 2025-2035)

  • In Vivo Gene Therapy
  • Ex Vivo Gene Therapy

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓